SCHEMBL2469602

SCHEMBL2469602

CCOC(=O)C(=O)C1COC(C)(C)CC1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.38
MAPT P10636 5/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
CYP2C19 P33261 1/20 0.37
HIF1A Q16665 1/20 0.35
KDM4E B2RXH2 3/20 0.35
TP53 P04637 1/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
GLO1 Q04760 1/20 0.34
TSHR P16473 2/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
GLA P06280 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16517229 0.75 ALDH1A1 (0.38) ALDH1A1MAPTL3MBTL1KMT2AMEN1
SCHEMBL2456370 0.75 MAPT (0.42) ALDH1A1MAPTL3MBTL1KMT2AMEN1
SCHEMBL2447326 0.73 ALDH1A1 (0.37) ALDH1A1MAPTL3MBTL1KMT2AMEN1
SCHEMBL23525062 0.72 ALDH1A1 (0.35) ALDH1A1MAPTL3MBTL1HIF1AKDM4E
SCHEMBL23567719 0.72 MAPT (0.37) ALDH1A1MAPTL3MBTL1HIF1AKDM4E
SCHEMBL16505741 0.69 ALDH1A1 (0.36) ALDH1A1MAPTL3MBTL1KMT2AMEN1
SCHEMBL22069412 0.68 MAPT (0.36) ALDH1A1MAPTL3MBTL1HIF1AKDM4E
SCHEMBL1149616 0.68 ALDH1A1 (0.38) ALDH1A1MAPTL3MBTL1KMT2AMEN1
SCHEMBL8197881 0.67 ALDH1A1 (0.45) ALDH1A1MAPTL3MBTL1KDM4ELMNA
SCHEMBL5109918 0.67 CYP2D6 (0.42) ALDH1A1MAPTL3MBTL1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 ALDH1A1 1042/4885MAPT 3569/4885L3MBTL1 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.